Division of Pediatric Hematology-Oncology, Maine Medical Center, 22 Bramhall Street, Portland, ME, 04102, USA,
Curr Oncol Rep. 2014;16(8):395. doi: 10.1007/s11912-014-0395-z.
Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.
儿科肉瘤是相对罕见的恶性肿瘤。作为一个整体，它们通常采用联合化疗和局部控制。幸运的是，这些恶性肿瘤通过仔细的临床试验合作进行了研究，以确定风险组，并适当地提供局部控制措施和系统治疗。尽管局部疾病通常以治愈为目的，但治疗通常持续超过 6 个月，并伴有严重的相关并发症。治疗转移性疾病或诱导持续缓解更为困难。在本文中，我们讨论了对疾病过程的理解的最新进展，并强调了最近和未来的骨肉瘤、尤文肉瘤、横纹肌肉瘤、非横纹肌肉瘤软组织肉瘤合作组试验，并讨论了有前途的治疗方法，如表观遗传学和免疫疗法。
